Stacey Lake, NP
Primary Care · Holladay, UTNPI 1154003473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations.
Across 158 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$355
- UCB, Inc.$334
- Viiv Healthcare Company$305
- Lilly USA, LLC$302
- AbbVie$262
- Johnson & Johnson$204
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,384100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $355 |
| UCB, Inc. | 14 | $334 |
| Viiv Healthcare Company | 10 | $305 |
| Lilly USA, LLC | 18 | $302 |
| AbbVie | 12 | $262 |
| Johnson & Johnson(2 entities) | 11 | $204 |
| AstraZeneca | 10 | $175 |
| Boehringer Ingelheim | 9 | $174 |
| Novo Nordisk | 4 | $146 |
| Novartis | 7 | $138 |
| Corcept Therapeutics | 4 | $127 |
| GSK | 6 | $95 |
| Gilead | 4 | $85 |
| Astellas Pharma US Inc | 1 | $80 |
| Pfizer | 4 | $55 |
| Fresenius Kabi USA, LLC | 3 | $51 |
| Edwards Lifesciences | 2 | $50 |
| Dynavax Technologies Corporation | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Exact Sciences | 2 | $33 |
| Radius Health, Inc. | 2 | $32 |
| Genentech USA, Inc. | 2 | $30 |
| Exeltis, USA Inc. | 1 | $29 |
| Tersera Therapeutics LLC | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $23 |
| Sandoz | 1 | $22 |
| Merck | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Vertex | 1 | $16 |
| Organon | 1 | $14 |
| Bayer | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,384 in reported general payments places this provider in the 85th percentile of 60 primary care providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $23,217 |
| JardianceEmpagliflozin | 18 | $22,320 |
| OzempicSemaglutide | 11 | $10,829 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,763 |
| Diclofenac Sodium | 16 | $789 |
| Omeprazole | 33 | $527 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $456 |
| Pantoprazole Sodium | 39 | $433 |
| Metformin Hcl ErMetformin Hcl | 49 | $429 |
| Losartan Potassium | 48 | $410 |
| Gabapentin | 23 | $398 |
| Atorvastatin Calcium | 39 | $384 |
| Tramadol Hcl | 23 | $375 |
| Tamsulosin Hcl | 18 | $330 |
| Escitalopram Oxalate | 47 | $318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $55 | $23,21731 claims |
| Boehringer IngelheimJardiance | $174 | $22,32018 claims |
| Novo NordiskOzempic | $146 | $10,82911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 60 primary care providers in Utah.
Other primary care in Holladay
- London JacksonSpringville$22K
- Tyler HobbsProvo$15K
- Jeffrey WalshBountiful$15K
- Marcella RowleyRiverton$13K
- Elizabeth WillmoreRiverton$6K
- Dustin ThompsonLayton$6K
- Catherine CoatesSalt Lake City$5K
- Liana KinikiniWest Jordan$4K
- Madeleine RupertSalt Lake City$3K
- Holly WortleyBountiful$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.